DIFFUSE ASTROCYTIC GLIOMA, IDH-WILDTYPE, WITH MOLECULAR FEATURES OF GLIOBLASTOMA, WHO GRADE IV
Clinical trials for DIFFUSE ASTROCYTIC GLIOMA, IDH-WILDTYPE, WITH MOLECULAR FEATURES OF GLIOBLASTOMA, WHO GRADE IV explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE ASTROCYTIC GLIOMA, IDH-WILDTYPE, WITH MOLECULAR FEATURES OF GLIOBLASTOMA, WHO GRADE IV trials appear
Sign up with your email to follow new studies for DIFFUSE ASTROCYTIC GLIOMA, IDH-WILDTYPE, WITH MOLECULAR FEATURES OF GLIOBLASTOMA, WHO GRADE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental trio therapy takes on recurrent glioblastoma
Disease control OngoingThis phase II trial tests whether combining two immunotherapy drugs (INCAGN1876 and INCMGA00012) with targeted radiation can help people with recurrent glioblastoma, an aggressive brain cancer. The 39 participants receive the drugs before and after surgery to remove the tumor, pl…
Matched conditions: DIFFUSE ASTROCYTIC GLIOMA, IDH-WILDTYPE, WITH MOLECULAR FEATURES OF GLIOBLASTOMA, WHO GRADE IV
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for recurrent brain cancer: drug combo aims to outsmart tumors
Disease control OngoingThis study tests a combination of two drugs (tocilizumab and atezolizumab) plus targeted radiation in people whose glioblastoma brain tumor has returned. The goal is to make the tumor more responsive to the body's immune system. About 59 adults will take part to find the best dos…
Matched conditions: DIFFUSE ASTROCYTIC GLIOMA, IDH-WILDTYPE, WITH MOLECULAR FEATURES OF GLIOBLASTOMA, WHO GRADE IV
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC